MGC Pharma completes delivery of first major ArtemiCTM Rescue order to Swiss PharmaCan AG, drives March to record quarter for MGC’s product revenues

Key Highlights:

•  In March 2021, the Company announced an initial purchase order for ArtemiCTM Rescue from Swiss PharmaCan AG (SPC), of approximately $425,000 (~ €275,000) wholesale revenue to MGC Pharma – with this first major batch order delivered to SPC in March.
•  MXC delivers record quarterly revenue from its phytomedicine products of approximately $880,000, inclusive of the first bulk order of ArtemiCTM Rescue from SPC.
•  The SPC Master Agreement signed includes a minimum wholesale order quantity to MGC Pharma of 40,000 units per quarter of ArtemiCTM Rescue.
•  Swiss PharmaCan AG to exclusively distribute ArtemiCTM Rescue worldwide1 , with specific focus on countries currently reporting high numbers of COVID-19 patients.
•  Sales growth of the Company’s pharma grade, cannabinoid products has continued in key markets including Australia in the first quarter of calendar 2021.
•  Completion of the Medicinal Cannabis Clinics (MCC) acquisition starts to deliver operational synergies and broader Australian patient access including new sales pipeline

Master supply agreement was on 18/2/21...previously posted...

 3/3/21 Swiss PharmaCan AG increases initial purchase order volume by 85% for first ArtemiCTM Rescue production batch

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02349339-6A1022883?access_token=83ff96335c2d45a094df02a206a39ff4

I remarked on 18/2 that I thought maybe a TH (trading Halt was coming) because of lack of details in MasterAgreement, esp $s for MXC...very happy to see the $s coming through

DISC: I hold

Ethics Committee Approval Granted for Phase III Clinical Trial of CimetrATM on Patients Diagnosed with COVID-19

Key Highlights:

•  MGC Pharma has received Ethics Committee approvals from Rambam Health Care Campus, Haifa and Nazareth Hospital EMMS in Israel, for the Phase III clinical trial to be undertaken on patients diagnosed with COVID-19 (“Trial”).
•  CimetrATM is designed with the scientific aim to target viral infections with inflammatory complications and was successfully evaluated on COVID-19 (SARS-CoV-2) infected patients in a double-blind placebo controlled, Phase II clinical trial.
•  MGC Pharma is fully funded to complete the Trial following the LSE IPO £6.5m raising in February 2021.
•  The Trial will evaluate the efficacy and safety of CimetrATM in the treatment of moderate hospitalised patients diagnosed with COVID-19 on a large patient group.
•  The name change to CimetrATM recognises the transfer of product under the Phase III clinical trial to an Investigational Medicinal Product (“IMP”) status, while ArtemiCTM will remain as a food supplement.
•  CimetrATM encapsulates Graft Polymer’s proprietary GraftBio™ SNEDDS technology (Self-Nano Emulsifying Drug Delivery System), a unique platform to deliver active ingredients more effectively in higher concentrations to the cells, improving the bioavailability of natural active ingredients.
•  The Trial will provide additional data for claims on the product as an IMP and provide essential data to plan for the future regulatory pathway for the registration of CimetrATM as a drug.
•  The Trial is expected to commence in early April and conclude in September 2021, with interim results expected in June and full study results in October 2021.
•  This Phase III clinical trial is currently going through regulatory approvals for additional clinical sites in Israel and Brazil.
•  MGC Pharma already has the required facilities, permits and approvals to start production of CimetrATM as an IMP.
•  MGC Pharma is planning a CimetrA™ development program that will support pre-clinical and clinical trials in additional inflammatory and autoimmune indications.

Disc: I hold...although with the injections now being run out over the world, investors may not see the need for these trials now (or maybe only, for the moment).  I think we still need all the trials we can  

Master Supply & Distribution agreement signed with Swiss PharmaCan AG for exclusive worldwide1 distribution of ArtemiCTM Rescue

• Key Highlights:
•  Minimum three (3) year exclusive worldwide1 supply and distribution agreement signed with leading European nutraceuticals producer and distributor, Swiss PharmaCan AG, for the distribution of ArtemiCTM Rescue as a food supplement
•  This agreement follows the completion of a successful phase II double-blind, placebocontrolled clinical trial on 50 COVID-19 patients across Israel and India that met all its primary and secondary endpoints
•  Agreement includes minimum wholesale order quantity to MGC Pharma of 40,000 units of ArtemiCTM Rescue per quarter
•  Initial wholesale order of 10,000 units received by MGC Pharma, which has a total retail market value of US$850,000 for Swiss PharmaCan AG
•  MGC Pharma to also produce and provide daily dosage immune support supplement ArtemiC™ Support, for daily use.
• •Swiss PharmaCan AG to exclusively distribute ArtemiCTM Rescue and ArtemiC™ Support worldwide1 , with specific focus on countries currently reporting high numbers of COVID-19
•  The Company has sufficient manufacturing capacity at its production facility in Slovenia to produce commercial scale batches of ArtemiCTM Rescue and ArtemiC™ Support for distribution by Swiss PharmaCan AG
•  Additionally, Swiss PharmaCan AG has already secured agreement with Relay Medical Corp. (CSE: RELA) and Glow LifeTech Ltd. for exclusive North American and Caribbean sales and distribution rights for ArtemiCTM Rescue and ArtemiC™ Prevention
•  Swiss PharmaCan AG has also secured ONASIS Holdings Corp. (OTC: ONSS) as Master Distributor of ArtemiC™ Rescue and ArtemiC™ Prevention through their channels in USA and Central America.

DISC~I Hold

Notes~ Master agreement & Annoucement not marked "Sensitive" ??

        ~Mentions Retail values, lacking in $'s for MXC...I see a TH coming

New In-vitro cannabinoid study on Glioblastoma treatment using proprietary nano-delivery platform to commence

Key Highlights:

~ MGC Pharma’s research program into the use of cannabinoids in the treatment of aggressive glioblastoma brain cancer has been expanded, in collaboration with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre

~ Preliminary results of MGC Pharma’s proprietary cannabinoid treatment of Glioblastoma have recently completed an independent peer review and been formally published in the MDPI (Multidisciplinary Digital Publishing Institute) Medical Journal

~ The new, expanded study will also explore the use of a nanoparticle delivery system to improve the effects of the glioblastoma treatment

~ Delivery system is similar to the nanoparticle delivery system being used successfully in MGC Pharma’s ArtemiCTM clinical trial into the treatment of COVID-19

~ In-vitro results to date show that MGC Pharma formulated cannabigerol (CBG) can eliminate therapy-resistant glioblastoma stem cells

~Successful study results would mean a key breakthrough for MGC Pharma in the treatment of aggressive brain cancers, one of its key target clinical research treatment areas – Oncology

~The new study will shortly commence recruitment of new patients with grade IV glioblastomas to be divided into subcategories to receive a personalised treatment plan

DISC: I Hold

MGC Pharma Welcomes Admission to the LSE & First Day of Trading

Key Highlights:

~Successful £6.5 million capital raising completed by way of an oversubscribed placement of 441 million ordinary shares at a price of 1.475 pence each to UK institutional funds, high net worth family office and professional investor clients of Turner Pope Investments

~ MGC Pharma becomes the first cannabis-sector company to IPO on the main market of the LSE in the UK

~ In FY2020 MGC Pharma generated revenue of AU$2.1m, delivering major revenue growth from FY2019 and a continuing upwards trend in FY2021

~ MGC Pharma’s existing products designed to meet immediate market concerns, including the two flagship phytocannabinoid-derived medicines: CannEpil® designed as a treatment for refractory epilepsy and CogniCann® designed to improve dementia and Alzheimer’s disease for patients’ quality of life

~ MGC Pharma has developed an affordable product range, its MP line, which leverages pharma-grade compounded products from high-CBD through to high-THC formulations

~ Company research is focused on treatment in three core areas: Neurology, Oncology, and Autoimmune diseases, and includes the development of ArtemiC™ for treatment of Covid-19 infected patients

~The net proceeds of the capital raise will be used to meet the costs associated with its priority clinical trials including ArtemiC™ and CannEpil®, as well as increasing distribution of the Group’s product range, general working capital and the completion of the Group’s manufacturing facilities in Malta

Disc: I hold

MGC Pharma set to become the first medicinal cannabis company to list on the London Stock Exchange

£6.5m (~A$12m) placement completed, led by UK institutional funds

Key Highlights:

• MGC Pharma is set to become the first medicinal cannabis related company to be admitted to the main market of the London Stock Exchange (LSE) through a standard listing, which is scheduled to take place on Tuesday, 9 February 2021

• MGC Pharma has secured binding commitments to raise £6.5 million (~A$12m), before costs, through a share placement to coincide with the Company’s imminent LSE listing

• Strategic placement to substantial UK institutional funds led by Premier Miton and Chelverton Asset Management, with high net worth family office and professional investor clients of London equity broker Turner Pope Investments Limited (Turner Pope)

• MGC Pharma will maintain a dual LSE and ASX listing to significantly broaden MGC Pharma’s international profile and specifically provide direct access to UK and European institutional and other investors, which aligns with the Company’s established and future European operations

• MGC Pharma set to fast-track commencement of ArtemiCTM Phase III clinical trials upon completion of the placing and LSE Listing, to be conducted across 3 continents and over 250 patients

DISC: I have small holding